- All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment
- Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes
- Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print
PR Newswire
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2018